Open AccessDesign of the NL‐ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
Author(s) -
Scheltens Nienke M.E.,
Kuyper Ingrid S.,
Boellaard Ronald,
Barkhof Frederik,
Teunissen Charlotte E.,
Broersen Laus M.,
Lansbergen Marieke M.,
Flier Wiesje M.,
Berckel Bart N.M.,
Scheltens Philip
Publication year - 2016
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2016.07.004
Subject(s) - synapse , dementia , alzheimer's disease , medicine , episodic memory , standardized uptake value , randomized controlled trial , disease , carbohydrate metabolism , neuroscience , positron emission tomography , psychology , cognition
Alzheimer's disease is associated with early synaptic loss. Specific nutrients are known to be rate limiting for synapse formation. Studies have shown that administering specific nutrients may improve memory function, possibly by increasing synapse formation. This Dutch study explores the Effect of a specific Nutritional Intervention on cerebral Glucose Metabolism in early Alzheimer's disease (NL-ENIGMA, Dutch Trial Register NTR4718, http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4718). The NL-ENIGMA study is designed to test whether the specific multinutrient combination Fortasyn Connect present in the medical food Souvenaid influences cerebral glucose metabolism as a marker for improved synapse function.